NCT06281119View on ClinicalTrials.gov

Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Human Papillomavirus Infection
Interventions
BIOLOGICAL

Cervavac as three dose regimen

Cervavac manufactured by Serum Institute of India Pvt Ltd administered as three doses at day 0, 60 and 180.

BIOLOGICAL

Cervavac as two dose regimen

Cervavac manufactured by Serum Institute of India Pvt Ltd administered as two doses at day 0 and 180.

BIOLOGICAL

Gardasil as three dose regimen

Gardasil manufactured by MSD administered as a three doses at day 0,60 and 180.

Trial Locations (4)

1929

Manhiça Health Research Center - Manhiça Foundation (CISM-FM), Manhiça

2092

Clinical HIV Research Unit (CHRU), Helen Joseph Hospital, Johannesburg

54840-00200

Centre For Clinical Research, Kemri, Nairobi

19865-00202

Partners in Health and Research Development (Phrd), Thika

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Serum Institute of India Pvt. Ltd.

INDUSTRY